• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Obituary Notice: Russell “Russ” Haines

    Abenza Chooses North Carolina for New Biologics Manufacturing Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Recro, Ensysce Expand Development and Manufacturing Partnership

    Metrics Names Stephanie Emory Associate Director of Pharma Development

    Albumedix Completes Commercial-Scale Mfg. Facility Expansion
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Obituary Notice: Russell “Russ” Haines

    Catalent Adds Cryogenic Capabilities at Philadelphia Facility

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Bristol Myers Squibb Expands at Cambridge Crossing

    Amgen Completes Five Prime Acquisition

    Sartorius Expands in the UK

    Abenza Chooses North Carolina for New Biologics Manufacturing Site

    Arkema Recruits Dotmatics as its R&D Digitalization Partner
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Ensuring Pharma Manufacturing Quality

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Aphena Pharma Solutions

    Adare Pharma Solutions

    PCI Pharma Services

    Reed-Lane

    Syngene
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Baxter BioPharma Solutions

    PCI Pharma Services

    Emergent BioSolutions

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Breaking News

    Prevail, Lonza Enter Development and Mfg. Alliance

    Lonza will manufacture Prevail's AAV-based gene therapy programs for neurodegenerative diseases

    Related CONTENT
    • Softweb Solutions
    • Vetio Animal Health
    • Mesoblast and Lonza Enter Manufacturing Agreement
    • Overcoming the Small Molecule Bioavailability Challenge
    • Cellectis and Lonza Enter cGMP Manufacturing Service Agreement
    10.08.19
    Prevail Therapeutics, a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, and Lonza have entered into a strategic collaboration.
     
    The two companies have been working together since 2018, with an initial focus on process development, towards the GMP manufacturing of Prevail's two lead programs, PR001 and PR006. Under this collaboration, focused on the baculovirus/Sf9 production system for gene therapies, Lonza will manufacture Prevail's pipeline of novel AAV-based gene therapy programs for patients with neurodegenerative diseases at its gene therapy center of excellence in Houston, TX.
     
    Prevail's pipeline includes PR001, an AAV9-based gene therapy delivering GBA1, in development for Parkinson’s disease patients with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease patients (nGD). Prevail plans to initiate a Phase 1/2 clinical trial of PR001 in PD-GBA in 2019. The company is also developing PR006, an AAV9-based gene therapy delivering GRN, for frontotemporal dementia patients with a GRN mutation (FTD-GRN). Prevail anticipates PR006 will enter the clinic in 2020. The collaboration also has the potential to extend to Prevail's future pipeline of AAV-based gene therapy programs.
     
    Prevail has built in-house process and analytical development capabilities utilizing both HEK293 and baculovirus/Sf9 AAV expression systems. Under this collaboration, Prevail and Lonza will work closely together on process development, analytical development, and large-scale production using the baculovirus/Sf9 process for late-stage clinical and commercial supply at Lonza’s GMP facility in Houston.
     
    "Prevail is a brilliant trailblazer and it is a privilege to partner with them,” Alberto Santagostino, senior vice president, head of cell and gene technologies, Lonza Pharma & Biotech. “This strategic collaboration reflects both companies' commitment to fueling the innovation of novel medicines. The partnership combines Prevail’s frontier science with Lonza’s operational expertise to support the development and commercialization of potentially life-changing treatments. Our cell and gene therapy center of excellence in Houston, TX, will support Prevail in their journey as they develop and potentially bring to market AAV-based gene therapies for patients suffering from debilitating neurodegenerative diseases. "
     
    Asa Abeliovich, founder and chief executive officer, Prevail Therapeutics, "We are pleased to partner with Lonza, a leader in the manufacturing of AAV gene therapy vectors, to enable large-scale production of our novel gene therapies that we believe hold potential to halt the course of neurodegenerative diseases for patient populations with urgent unmet needs.  Lonza and Prevail will work together closely on process development and scaling up production of PR001, our gene therapy for Parkinson’s disease with GBA1 mutations and neuronopathic Gaucher disease, to supply late-stage clinical trials and for commercial production. In addition, we look forward to a collaborative relationship to support our PR006 gene therapy program for patients with frontotemporal dementia with GRN mutations, and for future gene therapy programs in our pipeline."
    Related Searches
    • Pharma
    • collaboration
    • Analytical Development
    • biotechnology
    Suggested For You
    Softweb Solutions Softweb Solutions
    Vetio Animal Health Vetio Animal Health
    Mesoblast and Lonza Enter Manufacturing Agreement Mesoblast and Lonza Enter Manufacturing Agreement
    Overcoming the Small Molecule Bioavailability Challenge Overcoming the Small Molecule Bioavailability Challenge
    Cellectis and Lonza Enter cGMP Manufacturing Service Agreement Cellectis and Lonza Enter cGMP Manufacturing Service Agreement
    API to ADC: A Journey Through High Potency API to ADC: A Journey Through High Potency
    Lonza, Celltrion Sign Contract to Manufacture Remsima Drug Substance Lonza, Celltrion Sign Contract to Manufacture Remsima Drug Substance
    Omeros, Lonza Enter Commercial Manufacturing Agreement Omeros, Lonza Enter Commercial Manufacturing Agreement
    Lonza, Vineti Enter Cell and Gene Therapy Network Alliance Lonza, Vineti Enter Cell and Gene Therapy Network Alliance
    Lonza Expands Bioconjugation Facility and Third Commercial ADC Approved Lonza Expands Bioconjugation Facility and Third Commercial ADC Approved
    Lonza Selects Rockwell Automation for Digital Pharma Ops Lonza Selects Rockwell Automation for Digital Pharma Ops
    Lonza Completes $15M Tampa Site Expansion Lonza Completes $15M Tampa Site Expansion
    Lonza to Acquire Sterile Fill and Finish Facility from Novartis  Lonza to Acquire Sterile Fill and Finish Facility from Novartis
    Gamida Cell and Lonza to Manufacture Omidubicel Gamida Cell and Lonza to Manufacture Omidubicel
    Lonza to Expand HPAPI Development and Manufacturing Capacity Lonza to Expand HPAPI Development and Manufacturing Capacity

    Related Breaking News

    • Biologics, Proteins, Vaccines | Breaking News | Industry News
      Sartorius Expands in the UK

      Sartorius Expands in the UK

      New 58,000-square-foot facility aims to simplify and accelerate the production of downstream processing equipment.
      Kristin Brooks 04.16.21

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News
      Abenza Chooses North Carolina for New Biologics Manufacturing Site

      Abenza Chooses North Carolina for New Biologics Manufacturing Site

      GMP manufacturing will commence in mid-2022.
      Charles Sternberg, Assistant Editor 04.15.21

    • Biologics, Proteins, Vaccines | Breaking News | Industry News | Information Technology
      ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

      ATMPS, Ori Biotech Integrate Digital Platform for Cell & Gene Therapies

      Aims to provide improved product tracking, scheduling and live monitoring of the manufacturing status across the entire CGT supply chain from vein to vein.
      Kristin Brooks 04.14.21


    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
      Albumedix Completes Commercial-Scale Mfg. Facility Expansion

      Albumedix Completes Commercial-Scale Mfg. Facility Expansion

      Will service increasing demand for products and technologies for cell and gene therapies, vaccines, diagnostics, protein and peptide therapeutics.
      Kristin Brooks 04.14.21

    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
      Catalent Biologics Completes Madison Expansion

      Catalent Biologics Completes Madison Expansion

      More than doubles overall CGMP-scale capacity increasing the number of manufacturing suites at the site to five.
      Kristin Brooks 04.13.21

    • Biologics, Proteins, Vaccines | Breaking News | Industry News
      Sanofi Invests in Cutting Edge Vax Production Site in Singapore

      Sanofi Invests in Cutting Edge Vax Production Site in Singapore

      The factory will house several fully digitalized modules that allow production of three to four vaccines simultaneously.
      Kristin Brooks 04.12.21


    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      Sanofi Acquires Tidal Therapeutics

      Sanofi Acquires Tidal Therapeutics

      Gains novel mRNA-based technology with research capabilities in immuno-oncology and inflammatory diseases, with potential in other disease areas.
      Kristin Brooks 04.12.21

    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Fill/Finish | Industry News
      Moderna, Catalent Enter Long-Term Strategic Vax Pact

      Moderna, Catalent Enter Long-Term Strategic Vax Pact

      Catalent to dedicate a new high-speed vial filling line for the manufacture of the Moderna COVID-19 Vaccine and potentially other investigational programs.
      Kristin Brooks 04.06.21

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News | Parenterals
      Sanofi to Build New $700M Flu Vaccine Facility in Canada

      Sanofi to Build New $700M Flu Vaccine Facility in Canada

      Facility will be located in Toronto and will increase supply of influenza vaccines in Canada, the U.S. and Europe.
      Tim Wright, Editor, Contract Pharma 04.05.21


    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      Eloxx Pharmaceuticals Acquires Zikani Therapeutics

      Eloxx Pharmaceuticals Acquires Zikani Therapeutics

      Combined company brings complementary Ribosomal RNA-targeted genetic therapy platforms together.
      Kristin Brooks 04.01.21

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Fill/Finish | Industry News
      GSK Supports Manufacture of Novavax’ COVID-19 Vaccine

      GSK Supports Manufacture of Novavax’ COVID-19 Vaccine

      GSK will provide fill and finish manufacturing capacity for up to 60 million doses at its Barnard Castle facility.
      Tim Wright, Editor, Contract Pharma 03.31.21

    • Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
      Ajinomoto, Bright Peak Enter Immunocytokines Research Pact

      Ajinomoto, Bright Peak Enter Immunocytokines Research Pact

      Exclusive license agreement to incorporate Ajinomoto Co.’s AJICAP site-specific bioconjugation technology for the development of Bright Peak Immunocytokines.
      Kristin Brooks 03.30.21


    • Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News | Scale-up/Technology Transfer
      CureVac, Celonic Enter COVID-19 Vax Mfg. Pact

      CureVac, Celonic Enter COVID-19 Vax Mfg. Pact

      Celonic is prepared to manufacture more than 100 million doses of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV, per year at Heidelberg facility.
      Kristin Brooks 03.30.21

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Drug Development | Facilities | Industry News
      Chime Biologics Expands CDMO Capabilities

      Chime Biologics Expands CDMO Capabilities

      Completes $190 million financing round to accelerate capacity expansion.
      Tim Wright, Editor, Contract Pharma 03.29.21

    • Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Fill/Finish | Industry News | Parenterals
      Jubilant, Novavax Enter COVID-19 Vaccine Partnership

      Jubilant, Novavax Enter COVID-19 Vaccine Partnership

      Jubilant to provide fill-finish manufacturing services for the production of COVID-19 vaccine candidate NVX-CoV2373.
      Tim Wright, Editor, Contract Pharma 03.29.21

    Trending
    • Thermo Fisher Acquires PPD For $17.4B
    • Ensuring Pharma Manufacturing Quality
    • Bristol Myers Squibb Expands At Cambridge Crossing
    • Abenza Chooses North Carolina For New Biologics Manufacturing Site
    • Amgen Completes Five Prime Acquisition
    Breaking News
    • Bristol Myers Squibb Expands at Cambridge Crossing
    • Amgen Completes Five Prime Acquisition
    • Sartorius Expands in the UK
    • Obituary Notice: Russell “Russ” Haines
    • Abenza Chooses North Carolina for New Biologics Manufacturing Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    AstaReal Astaxanthin Ingredient Receives U.S. Patent Approval
    Study on Kemin’s DailyZz Botanical Blend Uncovers Sleep Quality, Next-Day Performance Benefits
    FDA’s Dr. Cara Welch Opening Speaker at the 9th AHPA Botanical Congress
    Coatings World

    Latest Breaking News From Coatings World

    Jebsen & Jessen, Innospec Sign Distribution Agreement
    IGL Coatings Announces Partnership in Finland
    Axalta Schedules 1Q 2021 Earnings Conference Call
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Iterative Scopes Announces IBD-Focused Scientific Advisory Board
    Vicarious Surgical, D8 Holdings Corp. Combine Operations in $1.1 Billion Deal
    FDA Grants De Novo Clearance to Medtronic’s GI Genius Model
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Bristol Myers Squibb Expands at Cambridge Crossing
    Amgen Completes Five Prime Acquisition
    Sartorius Expands in the UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Former L’Oréal Exec Joins Glossier
    Lancôme Reveals New Global Sustainability Program
    First-Ever Skincare Line Focuses on Iron To Prevent Aging
    Happi

    Latest Breaking News From Happi

    Fragrance Creators Association Celebrates P&G Executive
    Evonik Highlights Solutions for Malodor Reduction
    P&G Emphasizes Small Actions at Home To Be More Sustainable
    Ink World

    Latest Breaking News From Ink World

    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    SE-DA Invests in Kornit Presto S
    Acrylic Resins Market Worth $21.9 Billion by 2025: MarketsandMarkets
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    TLMI reveals Eugene Singer Award winners at Virtual Spring Summit
    Monadnock Paper Mills joins SGP
    ACTEGA helps converter reach sustainability goals
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Albaad to Add Natural-Based Line in Israel
    First Quality to Discontinue Tampon Operations
    Jessup Installs New Era Coating and Laminating Line
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    BioMagnetic Sciences Names President and CEO
    Mainstay Medical Launches ReActiv8 in Australia
    Biogennix Rolls Out Agilon Strip Bone Graft
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Virtual ASMC 2021 Spotlights Advanced Semiconductor Manufacturing Excellence
    LG Display Cuts Down CO2-eq Emissions by 3 Million Tons in 2020
    European Commission's Innovation Radar Acknowledges 3 ARMOR Innovations

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login